New Delhi -°C
Today in New Delhi, India

Feb 25, 2020-Tuesday
-°C

Humidity
-

Wind
-

Select city

Metro cities - Delhi, Mumbai, Chennai, Kolkata

Other cities - Noida, Gurgaon, Bengaluru, Hyderabad, Bhopal , Chandigarh , Dehradun, Indore, Jaipur, Lucknow, Patna, Ranchi

Home / Brand Post / Cell therapy options at Guameng-Li Biodicine and Taipei Medical University Hospital bring hope to cancer patients

Cell therapy options at Guameng-Li Biodicine and Taipei Medical University Hospital bring hope to cancer patients

The immuno-cell therapy developed by Guang-Li Biomedicine and Taipei Medical University Hospital uses the human body’s immune system to attack tumour cells.

brand-post Updated: Dec 02, 2019 13:37 IST
With cell therapy officially allowed in Taiwan, Guang-Li Biomedicine and Taipei Medical University Hospital are leading Taiwan’s many medical institutions and research units in legalizing cancer treatment programs.
With cell therapy officially allowed in Taiwan, Guang-Li Biomedicine and Taipei Medical University Hospital are leading Taiwan’s many medical institutions and research units in legalizing cancer treatment programs.

The immunotherapy used by Guang-Li Biomedicine and Taipei Medical University Hospital has created new hope for the terminal patients of cancer.

The international journals Cell and Science have reported that immuno-cell therapy belongs to the new generation of anti-cancer weapons. The immuno-cell therapy developed by Guang-Li Biomedicine and Taipei Medical University Hospital uses the human body’s immune system to attack tumour cells. This major breakthrough in cancer treatment has prolonged the life of many cancer patients who were previously incurable, even curing them.

With cell therapy officially allowed in Taiwan, Guang-Li Biomedicine and Taipei Medical University Hospital are leading Taiwan’s many medical institutions and research units in legalizing cancer treatment programs. The Guang-Li Experimental Center took advantage of stem cell storage patents and immune cell preparation technology, successfully submitted applications and received approval of CIK immune cell therapy for 12 solid cancers, bringing top medical technology to patients.

This major breakthrough in cancer treatment has prolonged the life of many cancer patients who were previously incurable, even curing them.
This major breakthrough in cancer treatment has prolonged the life of many cancer patients who were previously incurable, even curing them.

Lee, Kuan-Der, deputy dean of Taipei Medical University Hospital, said, “the clinical trial of the hospital and Guang-Li Biomedicine has been approved. Highly active Cytokine-induced killer cells (CIK) can be used on first to third-stage cancer patients who do not respond to treatment effectively, as well as patients in the fourth phase of solid cancer. This method is currently more effective to prolong life and cure cancer compared to other therapies.”

The indication of approved projects include: colorectal cancer, breast cancer, lung cancer, cervical cancer, ovarian cancer, kidney cancer, liver cancer, pancreatic cancer, nasopharyngeal cancer, stomach cancer, oesophageal cancer and cholangiocarcinoma.

In the past, cancer treatment, regardless of surgery, chemotherapy or radiation therapy was to remove tumor cells from the outside, but Taiwanese law already allows the use of autologous cells for autoimmune cell therapy, and there are many successful cases for patients with stable cancer. In addition, Taiwan has also opened up autologous chondrocyte transplantation, autologous fat stem cell transplantation, skin repair, wound healing, and articular cartilage regeneration.

About Taipei Medical University Hospital

Taipei Medical University Hospital is an international cancer center with more than 100 cancer authoritative physicians, providing cancer patients with consultation, diagnosis, treatment, care, tracking and prevention in one place, as well as high-quality integrated medical services at all stages.

About Guang-Li Biomedicine

Guang-Li Biomedicine has been involved in cell research since 2009 and has worked with many medical institutions in Taiwan to conduct cell culture for patients with stroke and gradual freezing. The experimental center is committed to improving cell culture and treatment technologies such as immune cells, mesenchymal stem cells, and hematopoietic stem cells, and promotes the popularization of cell therapy, so that patients who have experienced pain can use cell therapy early to fight diseases such as malignant tumours.

Source: Digpu

Disclaimer: The content is distributed by Digpu. No Hindustan Times journalist is involved in the creation of this content.